Deciphering the craniofacial morphology and its growth in patient with ACH could help assess the beneficial effects of promising medical treatments that are currently being developed to counteract the effects of activating FGFR3 mutations [15, 16]. This evidence concerns the gene FGFR3 and achondroplasia.